Form 8-K - Current report:
SEC Accession No. 0001564590-22-018297
Filing Date
2022-05-05
Accepted
2022-05-05 16:39:29
Documents
14
Period of Report
2022-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mnkd-8k_20220505.htm   iXBRL 8-K 30105
2 EX-99.1 mnkd-ex991_6.htm EX-99.1 240327
3 GRAPHIC gwmgello5syk000001.jpg GRAPHIC 8800
  Complete submission text file 0001564590-22-018297.txt   420262

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mnkd-20220505.xsd EX-101.SCH 5709
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mnkd-20220505_lab.xml EX-101.LAB 18667
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mnkd-20220505_pre.xml EX-101.PRE 11139
8 EXTRACTED XBRL INSTANCE DOCUMENT mnkd-8k_20220505_htm.xml XML 3410
Mailing Address 1 CASPER STREET DANBURY CT 06810
Business Address 1 CASPER STREET DANBURY CT 06810 818-661-5000
MANNKIND CORP (Filer) CIK: 0000899460 (see all company filings)

EIN.: 133607736 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50865 | Film No.: 22897067
SIC: 2834 Pharmaceutical Preparations